4.5 Article

Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication

Journal

VACCINE
Volume 28, Issue 32, Pages 5315-5322

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.05.045

Keywords

Intradermal; Vaccine; Ricin

Funding

  1. NIH [AI-056372, 5T32GM008203]

Ask authors/readers for more resources

Ricin toxin is a CDC level B biothreat. We have developed a ricin vaccine, RiVax, which is a recombinant mutant of ricin A chain. RiVax is safe, immunogenic and protective in mice when administered intramuscularly (IM). We have now attempted to increase the utility and immunogenicity of RiVax by administering it intradermally (ID) with or without alum. Without alum, Rivax administered by the ID and IM routes was equally immunogenic and protective. With alum, ID vaccinations were more immunogenic and protective against both systemic and mucosal challenge with ricin and superior in protecting animals from ricin-induced lung damage. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available